GoodRx (NASDAQ:GDRX) Price Target Lowered to $2.50 at The Goldman Sachs Group

GoodRx (NASDAQ:GDRX) had its target price lowered by research analysts at The Goldman Sachs Group from $4.00 to $2.50 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 16.01% from the stock’s current price.

GDRX has been the subject of a number of other research reports. UBS Group reduced their price target on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Jefferies Financial Group downgraded shares of GoodRx to a “hold” rating in a report on Thursday, January 22nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GoodRx in a research note on Friday. Leerink Partners restated an “outperform” rating and set a $3.00 price target on shares of GoodRx in a research report on Thursday. Finally, Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Five investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.33.

GoodRx Stock Performance

NASDAQ:GDRX traded up $0.29 during mid-day trading on Monday, hitting $2.16. The stock had a trading volume of 5,423,413 shares, compared to its average volume of 3,278,635. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. The company has a 50 day simple moving average of $2.51 and a 200-day simple moving average of $3.26. The stock has a market capitalization of $731.47 million, a price-to-earnings ratio of 23.84, a P/E/G ratio of 0.71 and a beta of 1.52. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. The company had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. GoodRx’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.09 earnings per share. On average, research analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Several large investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of GoodRx during the third quarter worth $33,000. Cetera Investment Advisers purchased a new position in GoodRx in the 2nd quarter worth about $50,000. Boothbay Fund Management LLC acquired a new stake in GoodRx during the 3rd quarter worth about $43,000. Meridian Wealth Management LLC purchased a new stake in GoodRx during the fourth quarter valued at about $29,000. Finally, Shay Capital LLC acquired a new position in shares of GoodRx in the third quarter worth about $47,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.